ArticleInternational journal of clinical and experimental medicine2015

Phase I study of icotinib, an EGFR tyrosine kinase inhibitor combined with IMRT in nasopharyngeal carcinoma.

Wei Hu et al.PubMed ↗Full text ↗

No numbers read from the abstract.